AbbVie ABBV announced that it has entered into a collaboration and option-to-license agreement with the San Diego-based private biotech Neomorph to develop molecular glue degraders for multiple ...

AbbVie (NYSE: ABBV) and Neomorph, Inc. today announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets across oncology and immunology.

(RTTNews) - Biogen Inc. (BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer's, rare neurological, and ...

You may like Watch people manipulate 3D holograms thanks to breakthrough technology; Astronomers simulate a star's final moments as it's swallowed by a black hole: 'Breaks like an egg' ...

Alien: Covenant: Gruesome image shows off deadly Neomorph. The film's big bad is not for the faint-hearted. Jacob Stolworthy. Friday 21 April 2017 11:06 BST. Comments. open image in gallery.

Per the terms of the deal, Neomorph will receive an undisclosed amount as an upfront payment from AbbVie. The San Diego company will also be eligible to receive up to $1.64 billion in aggregate ...